Masking interleukin-12 with a domain of the interleukin-12 receptor via a linker cleavable by tumour-associated proteases eliminates systemic immune-related adverse events and triggers potent therapeutic effects in mice bearing immunologically cold tumours.
- Aslan Mansurov
- Peyman Hosseinchi
- Jeffrey A. Hubbell